Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...
Space can be a wondrous place, and we've got the pictures to prove it ... at 4:46 a.m. CET (0346 GMT), close to midnight on the U.S. east coast. The flaming debris was part of the upper stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback